An FDA letter to Senate investigators appears to contradict one of Genentech’s main reasons for restricting the distribution of its cancer drug Avastin.
Last year, the company said it would no longer sell the drug to compounding pharmacies, which repackage Avastin for use in patients with eye disease. In an open letter, the company said it [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment